<PAGE>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549


                                   FORM 10-QSB

[X]     Quarterly  Report  pursuant  to  Section  13  or 15(d) of the Securities
        Exchange  Act  of  1934

        For  the  quarterly  period  ended  March  31,  2003

[ ]     Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act
        of  1934

        For  the  transition  period  from          to

        Commission  File  Number      001-14297
                                      ---------

                                MW Medical, Inc.
                                ----------------
        (Exact name of Small Business Issuer as specified in its charter)

Nevada                                      86-0907471
------                                      ----------
(State  or  other  jurisdiction  of         (IRS  Employer
incorporation  )                            Identification  No.)

                 6929 E. Cheney, Paradise Valley, Arizona 85253
                 ----------------------------------------------
                    (Address of principal executive offices)

                                 (480) 951-4366
                                 --------------

                 Issuer's telephone number, including area code


Check  whether  the issuer (1) filed all reports required to be filed by Section
13  or  15(d)  of  the  Securities  Exchange Act of 1934 during the preceding 12
months  (or  for  such  shorter period that the issuer was required to file such
reports),  and  (2) has been subject to such filing requirements for the past 90
days  [  X  ]  Yes    [  ]  No

State the number of shares outstanding of each of the issuer's classes of common
stock,  as  of  the  latest  practicable date: 99,822,443 Shares of Common Stock
outstanding  as  of  May  22,  2003.

Transitional  Small  Business Disclosure Format (Check one): Yes [   ] No [ X  ]



<PAGE>


                         PART I - FINANCIAL INFORMATION

Item  1.      Financial  Statements.

BASIS  OF  PRESENTATION

General

The accompanying unaudited financial statements have been prepared in accordance
with  the  instructions  to  Form  10-QSB  and,  therefore,  do  not include all
information  and  footnotes  necessary  for a complete presentation of financial
position,  results  of  operations,  cash  flows,  and  stockholders' deficit in
conformity  with  generally  accepted  accounting principles.  In the opinion of
management,  all adjustments considered necessary for a fair presentation of the
results  of  operations  and  financial position have been included and all such
adjustments  are  of a normal recurring nature.  Operating results for the three
months  ended March 31, 2003, are not necessarily indicative of the results that
can  be  expected  for  the  year  ending  December  31,  2003.

                                       2

<PAGE>


<TABLE>
<CAPTION>

                     MW MEDICAL, INC.
                CONSOLIDATED BALANCE SHEET



                                  (Unaudited)            (Audited)
                                   March 31,            December 31,
                                     2003                  2002
                                   ---------------------------------
<S>                                <C>            <C>
CURRENT ASSETS
  Cash                             $        907   $             937
  Accounts Receivable
  Inventory                                                       -
                                   ---------------------------------

  Other current assets

          Total current assets              907                 937

                                   $        907                 937
                                   =================================



            LIABILITIES AND STOCKHOLDERSDEFICIT

CURRENT LIABILITIES
  Accounts payable                 $     50,715   $          35,202
  Accrued expenses                       13,915             116,160
  Note payable - related party          803,285           1,012,903
                                   ---------------------------------


          Total current liabilities     867,915           1,164,265

COMMITMENTS AND CONTINGENCIES                 -

STOCKHOLDERS (DEFICIT)
  Common stock $.001 par value;
   authorized - 100,000,000
   shares issued and outstanding,
   99,822,443 and                        99,822              25,822
    25,822,443 at 3-31-03 and
    12-31-02 respectively
  Additional paid-in capital         14,421,633          13,699,602
  Note receivable from former parent
  Accumulated deficit               (15,388,463)        (14,888,752)
                                   ---------------------------------



        Total stockholders deficit     (867,008)         (1,163,328)
                                   ---------------------------------


                                   $        907                 937
                                   =================================




</TABLE>

<PAGE>


<TABLE>
<CAPTION>


                           MW MEDICAL, INC.
               CONSOLIDATED STATEMENT OF OPERATIONS
                            (UNAUDITED)

                                                    Three months ended March 31,
                                                    -----------------------------
                                                         2003          2002
                                                    -----------------------------
<S>                                                 <C>              <C>
Sales, net                                          $            -   $         -
Cost of sales                                                    -             -
                                                                     ------------
                                                                 -             -

General and administrative expenses                         99,092       117,007
Depreciation and amortization                                    -         9,677
Research and development                                         -         1,000
                                                    -----------------------------

            Total operating expenses                        99,092       127,684
                                                    -----------------------------
            Net operating loss                             (99,092)     (127,684)
                                                    -----------------------------

Interest expense                                          (400,619)      (15,542)
                                                    ------------------------------
                                                          (400,619)      (15,542)
                                                                     ------------
  Loss from continuing operations
     before income taxes                                  (499,711)     (143,226)
  Income tax expense                                                           -
                                                    -----------------------------


            NET LOSS                                $     (499,711)  $  (143,226)
                                                    =============================

  Net loss per weighted average share               $       (0.017)  $     (0.01)
                                                    =============================

  Weighted average number of common shares used to
    compute net loss per weighted average share         29,933,544    24,517,443
                                                    =============================
</TABLE>


<PAGE>


<TABLE>
<CAPTION>
                          MW MEDICAL, INC.
             CONSOLIDATED STATEMENT OF CASH FLOWS.


                                    For the Three Months ended March 31,
                                          2003          2002
                                    ------------------------------------
<S>                                 <C>             <C>

Cash flows from operating activities
    Net Loss                        $    (499,711)  $ (143,226)
    Adjustments to reconcile net
      loss to cash used in
      operating activities:
        Depreciation and amortization            -       9,677
        Deferred salaries                   83,490      88,037
        Interest expense                   400,619      15,542
        Changes in assets and liabilities
          Increase in accounts receivable
          Decrease (increase) in inventories
          Decrease (increase) in restricted
           cash                                              -
          Decrease (increase) in prepaid
          expenses and other receivables
          Increase in accounts payable
           and accrued expenses             15,513      14,339
          Increase in deposits                               -
                                    ---------------------------


            Net cash used in
            operating activities               (89)    (15,631)
                                    ---------------------------


  Cash flows used in investing activities
    Purchase of equipment                                                                         -

                                    For the Three Months ended March 31,
                                          2003          2002
                                    ------------------------------------
  Cash flows from financing activities
    Proceeds from line of credit                             -
    Proceeds from loans                         59      15,550

       Net cash provided by
        financing activities                    59      15,550
                                    ---------------------------

      (Decrease) increase in cash
       and cash equivalents                    -30         (81)

  Cash and cash equivalents at
   beginning of period                         937         209
                                    ---------------------------

  Cash and cash equivalents
   at end of period                            907   $     128
                                    ===========================

  Supplemental information
    Cash paid for interest          $            -   $       -
    Cash paid for income taxes                   -           -
</TABLE>

Supplemental  Disclosure
     During the quarter ended March 31, 2003, an officer forgave $46,031 of fees
     due  to her. This cancellation has been recorded as a capital contribution.
     Also,  an  officer received 74,000,000 shares of common stock at $0.005 per
     share  to reduce loans to her by $375,000. Interest expense of $375,000 was
     also  recorded  in this transaction since the stock was issued at less than
     market  value.

<PAGE>



                               MW Medical, Inc.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                           March 31, 2003 (Unaudited)


NOTE  A  -  SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES

Basis  of  presentation
-----------------------

The  accompanying  consolidated  financial  statements  have  been  prepared  in
accordance  with  generally  accepted accounting principles ("GAAP") for interim
financial  information  and  with  the instructions to Form 10-QSB. Accordingly,
they  do  not include all of the information and footnotes required by generally
accepted  accounting principles for complete financial statements. The unaudited
consolidated  financial  statements  and  notes  should,  therefore,  be read in
conjunction with the financial statements and notes thereto in the Annual Report
on  Form  10-KSB  for  the  year  ended  December  31,  2002.  In the opinion of
management,  all  adjustments  (consisting  of normal and recurring adjustments)
considered  necessary  for a fair presentation, have been included.  The results
of  operations  for  the  three-month  period  ended  March  31,  2003  are  not
necessarily indicative of the results that may be expected for the entire fiscal
year  2003.


NOTE  B  -  REALIZATION  OF  ASSETS

The  Company  was  in  the  business  of  manufacturing  and selling our primary
product,  the  MW 2000.  It was also in the business of designing and developing
microwave  technologies  for  dermatological  applications. Due to our financial
condition and filing for bankruptcy, it has written off our entire inventory and
currently  has  no  business  activities.

The  Company  had  been  suffering recurring losses from operations for the past
three  years  and  was  unable  to  continue  in its present state and filed for
bankruptcy  protection  in January 2002.   In November 2002, the courts approved
the  plan  of  reorganization  and  the  bankruptcy  was  closed.

In view of the matters described in the preceding paragraph, recoverability of a
major  portion  of  the recorded asset amounts shown in the accompanying balance
sheet  is  dependent  upon continued operations of the Company, which in turn is
dependent  upon  the  Company's  ability to meet its financing requirements on a
continuing  basis,  to  maintain present financing, and to succeed in its future
operations.  The financial statements do not include any adjustments relating to
the  recoverability  and classification of recorded asset amounts or amounts and
classification  of  liabilities  that  might  be necessary should the Company be
unable  to  continue  in  existence.


                                       4

<PAGE>

                                MW Medical, Inc.

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

                           March 31, 2003 (Unaudited)


NOTE  B  -  REALIZATION  OF  ASSETS  -  Continued



The Company is in the process of evaluating business opportunities for a reverse
merger  or  to  obtain  financing  that will allow creditors and shareholders to
realize  value  not  otherwise available to them at this time.  We, however, can
provide  no  assurance that we will be successful in completing a reverse merger
or  obtaining  financing.

                                       5

<PAGE>


Item 2.    Management's Discussion and Analysis of Financial Condition and
           Results  of  Operations.

We  were  incorporated under the laws of the state of Nevada on December 4, 1997
as  a  subsidiary  of  Dynamic  Associates,  Inc.  ("Dynamic")

We were in the business of manufacturing and selling our primary product, the MW
2000.  We  also  were  in  the  business  of  designing and developing microwave
technologies for dermatological applications. Due to our financial condition and
filing  for  bankruptcy, we wrote off our entire inventory and currently have no
business  activities.

Chapter  11  Bankruptcy  Petition

On  January  22,  2002,  we  filed a Petition for relief under Chapter 11 of the
Bankruptcy  Code.  The  Petition  was  filed  in United States Bankruptcy Court,
District  of  Arizona,  In  Re: MW MEDICAL, INC., a Nevada Corporation, Case No.
02-0108-90-PHX-RTB,  and  In  Re:  MICROWAVE  MEDICAL  CORPORATION, a California
Corporation,  Case  No.  02-01298-PHX-GBN.  The purpose of the bankruptcy was to
protect  the  business from our creditors while we reorganized and tried to work
out  a  plan  to  pay  our  debts.

A  plan of reorganization was filed with the court, and amended on May 29, 2002.
On  October  23,  2002 we requested that the court approve the report, close the
estate  and enter a final decree.  The final decree was approved on November 19,
2002  and  the  court  closed  the  Petition  for relief under Chapter 11 of the
Bankruptcy  Code.

Settlement  of  Secured  Claim

The  sixth  class  of  claims  and  interests in the bankruptcy were the secured
claims  and  therefore  not  discharged.  Jan  Wallace,  our president and chief
executive  officer,  was  the  only secured creditor.  From November 2000 to the
filing  for  bankruptcy, Ms. Jan Wallace had financed our operations in exchange
for a promissory note and security interest in all of our assets.  Ms. Wallace's
claim  approved  in  the  bankruptcy  was  $1,189,939.70  of  which  $50,000 was
considered  unsecured  and  placed  under a different class.  As a result of the
reorganization,  Ms.  Wallace received a new promissory note from the company in
the  amount  of  $1,139,939.70  to  be  payable on or before September 30, 2002.

As  we were unable to pay this amount when due, or after, we entered into a loan
agreement with Ms. Wallace that restructured this debt.  In accordance with this
agreement, dated March 15, 2003, Ms. Wallace agreed to provide further financial
support  for  a period of up to 90 days in an amount of no more than $50,000 and
to  accept  a new promissory note for a reduced amount of $945,775.30.  This new
note  extended  our  payment  due  date  to June 15, 2003.  In consideration, we
assigned  and transferred all of our patents, trademarks, and other intellectual
property to Ms. Wallace in exchange for the $326,897 reduction of the promissory
note  based on the former book value of these assets prior to their write off at
year  end  2002.  In  addition,  a  $375,000  portion  of  this revised note was
converted  into  74,000,000 shares on March 26, 2003, leaving a balance owing of
$570,775.30.    This  exchange  was  consistent  with the bankruptcy order which
recognized Ms.


                                       6

<PAGE>


Wallace's  security  interest  in  the  assets  transferred  and  allowed  for a
conversion  of the debt into our common stock at a price of one half of the then
current  market  price.

Following  this,  Ms.  Wallace  entered  into  negotiations  with  the  Pacific
Commercial  Group,  LLC  whereby it was contemplated that the Pacific Commercial
Group  would  be  assigned  the  promissory  note and stock.  The deal was never
consummated.

Reverse  Stock  Split

Currently  our  operations  are  at  a  standstill  and  we wrote off our entire
inventory.  In addition, we have issued a total of 99,822,443 out of 100,000,000
authorized  common  shares  and  are therefore unable to issue additional shares
without  increasing  the  authorized  shares or reducing the total issued shares
through  a  reverse  stock  split.  Management  has determined that it must seek
additional  funding  or other business relationships such as a merger or reverse
acquisition in order to proceed with an active business operation. While no such
relationships  or  funding  have  been identified as of yet, management believes
that the currently large number of issued and outstanding shares will effect the
consummation  of  any  such relationship and that a smaller number of issued and
outstanding shares will assist in management's attracting of funding sources and
merger  partners  on  terms  that  will  be  more  beneficial  to  us.

We  filed a Schedule 14A and called a shareholders meeting for December 2, 2002,
in  part,  to  seek  shareholder  approval for a reverse split on a basis of one
share  for  every  25 presently outstanding.  As a result of insufficient votes,
the  meeting  was  cancelled  and  no  approval  was  obtained.

The  board  is  now  proposing that the Company's common stock undergo a reverse
split  on  a  basis  of  one share for every 500 shares presently outstanding in
order  to  make  the  corporation  more  attractive  as a target for a merger or
reverse  acquisition  and  to allow the company to offer its stock to investors.
Shareholder  approval  of  this  reverse stock split will effectively reduce the
number  of shares  held  by  each  shareholder  as  well  as  the  total  number
of  shares  outstanding.  The  percentage  of  outstanding  shares owned by each
shareholder  prior  to the proposed split will remain the same.  We have filed a
new  preliminary  Schedule  14A  in contemplation of this reverse split, and are
planning  on having a new shareholders meeting in the second or third quarter of
2003  to  decide  this  action.

Plan  of  Operations

We  currently  have  no business activities.  Unless we can secure financing, we
will not be able to restart our operations.  With the economic downturn, we have
been  unable  to raise additional capital from outside sources and management is
unaware  of  any  reasonable  prospects  for  financing.  We  are  in process of
evaluating  other  business  interests.

Assets

Our total assets as of March 31, 2003 were $907, compared to total assets in the
amount  of  $937  on December 31, 2002.  Our only asset is cash in the amount of
$907.



                                       7

<PAGE>

Liabilities  And  Stockholders  Equity

Our  total  liabilities  as  of March 31, 2003 were $872 ,915, compared to total
liabilities  in  the  amount  of  $1,164,265 as of December 31, 2002.  Our total
current  liabilities  consisted of: (a)$867,915 in accounts payable; (b) accrued
expenses  of  $13,915;  and  (c)  notes  payable in the amount of $803,285.  The
decrease  in total liabilities is due to the settlement of the creditor's claims
under  the  approved  reorganization  plan  in  the  Chapter  11 Bankruptcy.  In
addition,  on March 15, 2003, we entered into a loan agreement with Ms. Wallace.
In  accordance  with  this  agreement,  Ms.  Wallace  agreed  to provide further
financial  support  for a period of 90 days in an amount of no more than $50,000
and  to  accept a new promissory note for a reduced amount of $945,775.30, which
extended  the  due  date for payment to June 15, 2003. The balance owing on this
promissory  note  is  $570,775.30.

On  March  31, 2003, we had a working capital deficit of $867,008, compared to a
working  capital  deficit  of  $1,163,328  on  December  31,  2002.

Results  of  Operations

Due  to our financial condition and the filing of bankruptcy, we had no business
operations in the three month period ended March 31, 2003.  Therefore, we had no
revenue  for  the  three  month  period  ended  March  31,  2003.

Our  operating  expenses were $99,092 for the three month period ended March 31,
2003, compared to operating expenses of $127,684 for the same three month period
in  the  prior year.  Our only operating expense in the three month period ended
March  31,  2003 consisted of only general and administrative expenses.   We did
incur  $400,619  in  interest  expense in the three month period ended March 31,
2003,  compared to interest expense of 15,542 for the same three month period of
the  prior  year.

We  incurred  a  net loss of $499,711 for the three month period ended March 31,
2003,  compared to a net loss of $143,226 for the same three month period in the
prior  year.

Liquidity  and  Capital  Resources

On March 31, 2003 we had cash in the amount of $907, compared to $937 in cash on
December 31, 2002.  We wrote off our inventory and assigned it to Ms. Wallace to
repay  a  portion of the secured debt owed to her.  Therefore, our only asset is
cash.

Unless  we  can secure financing, we will not be able to restart our operations.
With  the  economic  downturn,  the  Company has been unable to raise additional
capital  from  outside  sources  and  management  is  unaware  of any reasonable
prospects  for  financing.



                                       8

<PAGE>

Forward-Looking  Statements

Many  statements made in this report are forward-looking statements that are not
based  on  historical  facts.  Because  these forward-looking statements involve
risks  and  uncertainties,  there  are important factors that could cause actual
results  to  differ  materially  from  those  expressed  or  implied  by  these
forward-looking  statements.  The forward-looking statements made in this report
relate  only  to  events  as  of  the  date  on  which  the statements are made.


ITEM  3.     CONTROLS  AND  PROCEDURES.

As  required  by  Rule  13a-15  under  the  Securities Exchange Act of 1934 (the
"Exchange Act"), we carried out an evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures within the 90 days prior
to  the  filing  date of this report.  This evaluation was carried out under the
supervision  and  with the participation of our Chief Executive Officer, Ms. Jan
Wallace and Chief Financial Officer, Ms. Grace Sim.  Based upon that evaluation,
our  Chief  Executive  Officer  and  Chief  Financial Officer concluded that our
disclosure  controls  and procedures are effective in timely alerting management
to  material  information  relating to us that is required to be included in our
periodic  SEC  filings.  There  have been no significant changes in our internal
controls  or  in other factors that could significantly affect internal controls
subsequent  to  the  date  we  carried  out  our  evaluation.

Disclosure  controls  and  procedures are controls and other procedures that are
designed  to  ensure  that  information  required to be disclosed in our reports
filed or submitted under the Exchange Act is recorded, processed, summarized and
reported,  within  the  time  periods  specified  in the Securities and Exchange
Commission's  rules  and  forms.  Disclosure  controls  and  procedures include,
without  limitation, controls and procedures designed to ensure that information
required  to  be  disclosed  in  our  reports  filed  under  the Exchange Act is
accumulated  and  communicated  to  management,  including  our  Chief Executive
Officer  and  Chief  Financial  Officer,  to  allow  timely  decisions regarding
required  disclosure.


                                       9

<PAGE>

PART  II  -  OTHER  INFORMATION

Item  1.          Legal  Proceedings:

Other  than as follows, we are not a party to any material litigation and to our
knowledge,  no  such  proceedings  are  threatened  or  contemplated.

On  January  22,  2002,  we  filed a petition for relief under Chapter 11 of the
United  States  Bankruptcy  Code.  The  petition  was filed in the United States
Bankruptcy Court, District of Arizona, under Case Number 02-01090-PHX-RTB for MW
Medical  Inc.  and  Case  Number  02-01298-PHX-GBN  for  Microwave Medical Corp.

A  plan of reorganization was filed with the court, and amended on May 29, 2002.
On  October  23,  2002 we requested that the court approve the report, close the
bankruptcy  and enter a final decree.  The final decree was approved on November
19,  2002  by  the court closing the Petition for relief under Chapter 11 of the
Bankruptcy  Code.

On February 25, 2003, MW Medical Corporation a/k/a Microwave Medical Corporation
was  named  and served as a third-party defendant in an action in New York state
court.  The  original  complaint  was  filed  by Arylnn Willis against Steven A.
Victor,  M.D.  and  Madison  Avenue  Dermatology  Center. Our bankruptcy counsel
believes  that  this  complaint will be dismissed as to us due to the bankruptcy
discharge.


Item  2.     Changes  in  Securities  and  Use  of  Proceeds:

In  Exchange  for a reduction of $375,000 and the issuance of a revised note, on
March  26,  2003 we issued 74,000,000 shares to our President and sole director,
Jan  Wallace.    This  exchange  was  consistent with the bankruptcy order which
recognized  Ms. Wallace's security interest in all of our assets and allowed for
a  conversion  of  her  debt into our common stock at a price of one half of the
then  current  market  price.

Item  3.          Defaults  Upon  Senior  Securities:

Up  through  the settlement of the secured promissory note held by our President
and  sole  director,  Ms.  Jan  Wallace, we were in default on our obligation to
repay  her  $1,189,939.70  as  required  under  our  plan  of  reorganization in
bankruptcy.

Item  4.     Submission  of  Matters  to  a  Vote  of  Security  Holders:

We  scheduled  a meeting of shareholders in January of this year, but a vote was
not taken due to an inadequate number of shares available to vote on the matters
submitted.


Item  5.          Other  Information:

None

                                       10

<PAGE>

Item  6.  Exhibits  and  Reports  on  Form  8-K.

EXHIBITS  REQUIRED  BY  ITEM  601  OF  REGULATION  SB


Exhibit Number     Description of Exhibit
--------------------------------------------------------------------------------
2.1                Bankruptcy  Order  Confirming  Debtor's  First Amended Joint
                   Plan  of  Reorganization

99.1               Certification  of  Chief  Executive  Officer  pursuant to 18
                   U.S.C.  Section  1350, as adopted pursuant to Section 906 of
                   the  Sarbanes-Oxley  Act  of  2002  (1)

99.2               Certification  of  Chief  Financial  Officer  pursuant to 18
                   U.S.C.  Section  1350, as adopted pursuant to Section 906 of
                   the  Sarbanes-Oxley  Act  of  2002  (1)
--------------------------------------------------------------------------------

(1)     Filed  as  an  Exhibit  to  this  Quarterly  Report  on  Form  10-QSB

--------------------------------------------------------------------------------


REPORTS  ON  FORM  8-K

On  March  31,  2003,  we  filed  a  Form 8-K to disclose a settlement agreement
entered  into  with  Ms.  Jan Wallace.  This agreement, in part, facilitated the
transfer  of our patents, trademarks and other intellectual property, inventory,
equipment  and other property in exchange for Ms. Wallace reducing the amount of
debt  due  to  Ms.  Wallace.  In  addition,  the Form 8-K also disclosed that we
entered  into a settlement agreement with our CEO and CFO, Jan Wallace and Grace
Sim  for  payment  of  unpaid  wages.


<PAGE>


                                   SIGNATURES

In  accordance  with  the  requirements  of the Exchange Act, the registrant has
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                         MW  Medical,  Inc.


DATED:    May  29,  2003
                          /s/ Jan  Wallace
                         ____________________________________
                         Jan  Wallace,  Chief  Executive  Officer



<PAGE>
                                 CERTIFICATIONS

I,  Jan Wallace, Chief Executive Officer of MW Medical, Inc. (the "Registrant"),
certify  that;

(1)  I  have  reviewed  this quarterly report on Form10-QSB of MW Medical, Inc.;

(2)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of a material fact or omit to state a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;

(3)  Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  Registrant  as  of,  and for, the periods presented in this
     quarterly  report;

(4)  The  Registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules  13a-14  and  15d-14) for the Registrant and have:

     a)   designed  such  disclosure  controls  and  procedures  to  ensure that
          material  information  relating  to  the  Registrant,  including  its
          consolidated  subsidiaries, is made known to us by others within those
          entities,  particularly  during  the  period  in  which this quarterly
          report  is  being  prepared;

     b)   evaluated  the  effectiveness  of the Registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this  quarterly  report  (the  "Evaluation  Date");  and

     c)   presented  in  this  quarterly  report  our  conclusions  about  the
          effectiveness  of  the disclosure controls and procedures based on our
          evaluation  as  of  the  Evaluation  Date;

(5)  The  Registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the Registrant's auditors and the audit
     committee  of  Registrant's  board  of directors (or persons performing the
     equivalent  functions):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which  could  adversely  affect  the Registrant's ability to
          record,  process,  summarize  and  report  financial  data  and  have
          identified  for  the  Registrant's auditors any material weaknesses in
          internal  controls;  and


     b)   any  fraud, whether or not material, that involves management or other
          employees  who  have  a  significant role in the Registrant's internal
          controls;  and


(6)  The  Registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  facts  that  could  significantly  affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.





Date:   May  29,  2003          /s/ Jan  Wallace
                                ___________________________________
                                Jan  Wallace
                                Chief  Executive  Officer


<PAGE>

                                 CERTIFICATIONS

I,  Grace  Sim,  Chief Financial Officer of MW Medical, Inc. (the "Registrant"),
certify  that;

(1)  I  have  reviewed  this quarterly report on Form10-QSB of MW Medical, Inc.;

(2)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of a material fact or omit to state a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;

(3)  Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  Registrant  as  of,  and for, the periods presented in this
     quarterly  report;


(4)  The  Registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules  13a-14  and  15d-14) for the Registrant and have:

     a)   designed  such  disclosure  controls  and  procedures  to  ensure that
          material  information  relating  to  the  Registrant,  including  its
          consolidated  subsidiaries, is made known to us by others within those
          entities,  particularly  during  the  period  in  which this quarterly
          report  is  being  prepared;

     b)   evaluated  the  effectiveness  of the Registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this  quarterly  report  (the  "Evaluation  Date");  and

     c)   presented  in  this  quarterly  report  our  conclusions  about  the
          effectiveness  of  the disclosure controls and procedures based on our
          evaluation  as  of  the  Evaluation  Date;

(5)  The  Registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the Registrant's auditors and the audit
     committee  of  Registrant's  board  of directors (or persons performing the
     equivalent  functions):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which  could  adversely  affect  the Registrant's ability to
          record,  process,  summarize  and  report  financial  data  and  have
          identified  for  the  Registrant's auditors any material weaknesses in
          internal  controls;  and

     b)   any  fraud, whether or not material, that involves management or other
          employees  who  have  a  significant role in the Registrant's internal
          controls;  and

(6)  The  Registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  facts  that  could  significantly  affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.




Date:   May  29,  2003          /s/ Grace  Sim
                                ___________________________________
                                Grace  Sim
                                Chief  Financial  Officer